Today's Top Performers In Drugs

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 66 points (0.4%) at 14,999 as of Wednesday, July 3, 2013, 12:51 PM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,690 declining with 89 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Vertex Pharmaceuticals ( VRTX), up 1.5%, Celgene Corporation ( CELG), up 1.2% and Biogen Idec ( BIIB), up 0.6%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 1.1%, and Eli Lilly and Company ( LLY), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Grifols ( GRFS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Grifols is up $0.50 (1.7%) to $29.73 on average volume. Thus far, 266,173 shares of Grifols exchanged hands as compared to its average daily volume of 636,800 shares. The stock has ranged in price between $28.90-$29.74 after having opened the day at $29.04 as compared to the previous trading day's close of $29.23.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $16.5 billion and is part of the health care sector. Shares are up 14.4% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is up $0.65 (0.7%) to $96.00 on light volume. Thus far, 300,507 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $94.11-$96.42 after having opened the day at $94.54 as compared to the previous trading day's close of $95.35.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.7 billion and is part of the health care sector. Shares are up 1.7% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexion Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $2.05 (0.9%) to $233.17 on light volume. Thus far, 268,154 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $229.03-$234.46 after having opened the day at $229.20 as compared to the previous trading day's close of $231.12.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $22.1 billion and is part of the health care sector. Shares are up 34.5% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null